Table 1 Backgrounds of the study patients.
From: Pretreatment PSA levels affects the completion rate of Ra-223 treatment
Complete arm | Incomplete arm | |
|---|---|---|
Number of activities (mean) | 5–6 (5.9) | 1–4 (2.9) |
Cases | 30 | 10 |
Age (mean) | 54–90 (70.5) years | 59–86 (71.1) years |
PS | ||
0 | 28 | 7 |
1 | 2 | 2 |
2 | 0 | 1 |
Use of bone modifying agents | ||
Yes | 18 | 8 |
No | 12 | 2 |
Previous abiraterone or enzalutamide | ||
Yes | 21 | 8 |
No | 9 | 2 |
Previous chemotherapy (docetaxel or cabazitaxel) | ||
Yes | 13 | 8 |
No | 17 | 2 |
PSA before Ra-223 treatment (ng/ml) [median] | 0.01–860.25 [5.88] | 22.49–2259.18 [113.15] |
< 10 | 17 | 0 |
≥ 10, < 100 | 9 | 5 |
≥ 100, < 1000 | 2 | 4 |
≥ 1000 | 2 | 1 |
ALP before Ra-223 treatment (U/L) [median] | 135–1499 [245] | 136–535 [228] |
BAP before Ra-223 treatment (ng/L) [median] | 6.4–141 [12.9] | 8.5–49.9 [13.1] |
Extent of bone disease | ||
2–5 metastases | 14 | 3 |
6–20 metastases | 7 | 0 |
> 20 metastases | 9 | 7 |
Superscan | 0 | 0 |
